Ethos Financial Group LLC Buys Shares of 6,925 DexCom, Inc. (NASDAQ:DXCM)

Ethos Financial Group LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,925 shares of the medical device company’s stock, valued at approximately $539,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc bought a new stake in DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the fourth quarter worth $38,000. SBI Securities Co. Ltd. acquired a new stake in DexCom in the fourth quarter valued at $49,000. Finally, Midwest Capital Advisors LLC bought a new position in DexCom during the 4th quarter worth $54,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of analyst reports. Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Canaccord Genuity Group increased their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Down 3.0 %

Shares of NASDAQ:DXCM opened at $79.51 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business’s 50 day simple moving average is $84.88 and its two-hundred day simple moving average is $76.96. The firm has a market cap of $31.07 billion, a P/E ratio of 55.60, a PEG ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 over the last three months. 0.30% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.